TY - JOUR
T1 - Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia
AU - McKiernan, James M.
AU - Lowe, Franklin C.
PY - 1997/5
Y1 - 1997/5
N2 - In this report, we assess the safety of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia. We analyzed seven prospectively designed placebo-controlled trials involving 3,080 patients, 1,689 of whom received the study drug in doses ranging from 1 mg to 20 mg daily for a total of 1,282 patient-years of exposure. The most common side effects seen in treated patients were dizziness (10.7%), asthenia (7.5%), and peripheral edema (4.0%). These side effects were generally reported as mild and improved after cessation of therapy. The incidence of withdrawal from the study due to side effects was 14.5% in the treatment arm versus 11.4% in the placebo control arm. Also noted was a statistically significant decreased risk of urinary tract infection and myocardial infarction in the terazosin- treated group. This updated report confirms that terazosin can be administered safely to a population of men with symptomatic benign prostatic hyperplasia with minimal clinically significant side effects.
AB - In this report, we assess the safety of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia. We analyzed seven prospectively designed placebo-controlled trials involving 3,080 patients, 1,689 of whom received the study drug in doses ranging from 1 mg to 20 mg daily for a total of 1,282 patient-years of exposure. The most common side effects seen in treated patients were dizziness (10.7%), asthenia (7.5%), and peripheral edema (4.0%). These side effects were generally reported as mild and improved after cessation of therapy. The incidence of withdrawal from the study due to side effects was 14.5% in the treatment arm versus 11.4% in the placebo control arm. Also noted was a statistically significant decreased risk of urinary tract infection and myocardial infarction in the terazosin- treated group. This updated report confirms that terazosin can be administered safely to a population of men with symptomatic benign prostatic hyperplasia with minimal clinically significant side effects.
UR - http://www.scopus.com/inward/record.url?scp=0030929074&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030929074&partnerID=8YFLogxK
U2 - 10.1097/00007611-199705000-00009
DO - 10.1097/00007611-199705000-00009
M3 - Article
C2 - 9160069
AN - SCOPUS:0030929074
SN - 0038-4348
VL - 90
SP - 509
EP - 523
JO - Southern Medical Journal
JF - Southern Medical Journal
IS - 5
ER -